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Abstract
The rhabdoid tumor (RT) predisposition syndromes 1 and 2 (RTPS1 and 2) are rare genetic conditions rendering young chil-
dren vulnerable to an increased risk of RT, malignant neoplasms affecting the kidney, miscellaneous soft-part tissues, the liver 
and the central nervous system (Atypical Teratoid Rhabdoid Tumors, ATRT). Both, RTPS1&2 are due to pathogenic variants 
(PV) in genes encoding constituents of the BAF chromatin remodeling complex, i.e. SMARCB1 (RTPS1) and SMARCA4 
(RTPS2). In contrast to other genetic disorders related to PVs in SMARCB1 and SMARCA4 such as Coffin-Siris Syndrome, 
RTPS1&2 are characterized by a predominance of truncating PVs, terminating transcription thus explaining a specific cancer 
risk. The penetrance of RTPS1 early in life is high and associated with a poor survival. However, few unaffected carriers may 
be encountered. Beyond RT, the tumor spectrum may be larger than initially suspected, and cancer surveillance offered to 
unaffected carriers (siblings or parents) and long-term survivors of RT is still a matter of discussion. RTPS2 exposes female 
carriers to an ill-defined risk of small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT), which may appear 
in prepubertal females. RT surveillance protocols for these rare families have not been established. To address unresolved 
issues in the care of individuals with RTPS and to propose appropriate surveillance guidelines in childhood, the SIOPe 
Host Genome working group invited pediatric oncologists and geneticists to contribute to an expert meeting. The current 
manuscript summarizes conclusions of the panel discussion, including consented statements as well as non-evidence-based 
proposals for validation in the future.
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The genetics of Malignant Rhabdoid Tumors 
(MRT)
MRT are rare, highly aggressive embryonal malignancies 
affecting predominantly infants and rather young children 
often below 3 years of age. They may affect any anatomical 
structure, commonly the central nervous system (i.e. Atypi-
cal Teratoid Rhabdoid Tumor, ATRT) where > 50% arise in 
the cerebellum [1]. Further common anatomical sites include 
extracranial, extrarenal tissues (eMRT; e.g. head and neck, 
paravertebral muscles, liver, bladder, mediastinum, ret-
roperitoneum, extremities, pelvis, and heart) and kidneys 
(RTK—rhabdoid tumor of the kidney).
MRT are characterized by a remarkably simple genome, 
with an extremely low number of single nucleotide vari-
ants per mega base and few recurrent PVs apart from those 
affecting the gene SMARCB1. SMARCB1 encodes the pro-
tein BAF47, which is a core-member of the BAF chroma-
tin remodeling complex. More than 90% of MRT harbor 
biallelic loss of function of SMARCB1; the few remaining 
cases show a loss of function of the SMARCA4 gene, which 
encodes BRG1, the helicase/ATPase protein of the BAF 
complex [2]. Taken together, MRT are an aggressive malig-
nancy of early childhood characterized by the disruption of 
the BAF complex in an otherwise stable genome.
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Pedigrees with several affected siblings have for long 
suggested that this malignancy could occur in a cancer 
predisposition syndrome, Rhabdoid Tumor Predisposition 
Syndrome (RTPS) [3]. Ever since the first description and 
identification of PVs in SMARCB1 and SMARCA4 as caus-
ative genetic events, compelling evidence has accumulated 
that MRT are frequently associated with genetic lesions in 
the germline. Many aspects of the clinical care for patients 
with RTPS remain unresolved however, especially as little 
consistency may be deducted due to small case numbers.
The SIOP Europe Host Genome Working Group has 
held a consensus meeting to update our knowledge on 
RTPS and to address unresolved issues. In a group dis-
cussion among human geneticists, pediatric oncologists 
and biologists we first asked whether the lack of evidence 
should deter us from providing recommendations based on 
the current admittedly modest evidence. All participants 
supported communicating provisional guidelines, as the 
rarity of the disease and an urgent clinical need call for 
expert recommendations.
The current manuscript provides an overview of the 
current knowledge and summarizes main conclusions 
drawn from the panel discussion.
RTPS1 and RTPS2: current knowledge
Epidemiology
Among 384 patients registered to the European Rhabdoid 
Registry (EU-RHAB), the median age at diagnosis was 18 
(0–211) months for ATRT (n = 244), 13.5 (0–207) months 
for eMRT (n = 89), 13 (2–166) months for RTK (n = 34) 
and 3 (0–23) months for synchronous multifocal MRT 
(n = 17) (M. Frühwald’s currently unpublished data). All 
available series report a male predominance with 1.3–1.5 
male: 1 female. The age-standardized annual incidence 
rate is between five (extracranial rhabdoid tumors) and 
eight per million (ATRT) in children below 1 year of age 
and decreases to between 0.6 and 2.2 per million at 1 to 
4 years [4, 5]. In the US, the annual incidence among chil-
dren less than 15 years is 0.89 per million for ATRT, 0.32 
per million for eMRT and 0.19 per million for RTK [6].
Rhabdoid Tumor Predisposition Syndromes (RTPS) 
are characterized by heterozygous germline PVs leading 
to inactivation of SMARCB1 (commonly) or SMARCA4 
(rarely) which are inherited in an autosomal dominant 
fashion. Among newly diagnosed cases of MRT 25–35% 
carry a germline PV in SMARCB1 (RTPS1) [7–9]. Given 
the rarity of cases with a SMARCA4 germline PV the exact 
incidence of RTPS2 is unknown.
Increased rhabdoid tumor risk in carriers 
of germline variants
In patients with RTPS, Rhabdoid Tumors have been 
reported in close to any anatomical localization [4, 5, 10]; 
in order of decreasing frequency: brain, kidney, soft tis-
sues, liver, skin, and others.
RTPS appear to be characterized by a few clinical 
features:
• Tumors may be detected pre- [11] or perinatally [12]; 
RTPS is diagnosed in about 66 to 80% of patients with 
congenital MRT [12, 13].
• Patients with RTPS are diagnosed at a median age of 
four to seven months (range: prenatally—60 months) 
compared to individuals with sporadic MRT (median 
age around 18 months, range: age 1 day—228 months) 
[14, 15]; almost all cases of MRT with germline 
mutations will be confirmed before the age of 2 years 
(Fig. 1b).
• Up to 1/3 of patients with RTPS have multiple (syn-
chronous–multifocal) tumors, with bifocal manifesta-
tion most commonly in kidney and brain [8].
In patients with RTPS1 penetrance may be extremely high 
(e.g. > 90% by 5 years) [12, 14, 16]. This statement may 
however be based upon selection bias and larger series 
of systematically screened trios (parents and affected off-
spring) are needed to more precisely define penetrance.
We know even less about the penetrance of RTPS2. Wider 
use of gene panels including SMARCB1 and SMARCA4 
among many other genes may reveal more carriers of a PV 
with no cancer phenotype. One needs to keep in mind the 
risk of ascertainment bias in these rare syndromes.
Increased risk of other neoplasms in RTPS
Given the low survival rate and high penetrance in childhood 
the risk for subsequent cancers cannot yet be extrapolated 
with adequate accuracy. Only a few teenagers and adults 
with RTPS1 have been reported, either as long-term survi-
vors or as, rather rarely, clinically unaffected carriers. Other 
tumor types including epithelioid schwannomas [17], malig-
nant peripheral nerve sheath tumors [14], myeloid sarcoma 
[18], meningioma [19, 20], benign myoepithelioma [19], 
chondrosarcoma [21] and ganglioglioma [22] have been 
reported. Rarely, ATRT occur in adult mutation carriers, 
e.g. a sellar ATRT-like tumor was described in a 51 year-old 
mother of two children who died from MRT [23].
Intriguingly, RTPS1 and multiple schwannomatosis 
may overlap. SMARCB1 germline PVs are responsible 
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for about 40% of inherited “schwannomatosis” and 10% 
of apparently sporadic cases, characterized by the devel-
opment of multiple indolent schwannomas [24]. Inter-
estingly, even though these schwannomas show some 
rhabdoid features and loss of INI1/BAF47 staining, they 
are distinct from MPNST with SMARCB1 loss. Rare 
patients/pedigrees affected by both tumor types have been 
observed, in line with a rather robust genotype–phenotype 
correlation [17, 25, 26]. While missense PVs and exon 1 
frameshifts that cause a re-initiation codon are associated 
with schwannomatosis, large deletions and premature stop 
codons resulting from nonsense PVs and intragenic dele-
tions almost exclusively predispose to MRT (Fig. 1a). A 
few contradictory examples have been reported. Notably, 
hypomorphic variants may occasionally induce both MRT 
and schwannomatosis, synchronously or metachronously 
[17, 25] PVs affecting splice sites have been encountered 
in both conditions.
Given its rarity, the cancer spectrum in RTPS2 has not 
been fully defined yet. However, RTPS2 and Small Cell 
Carcinoma of the Ovary, Hypercalcemic type (SCCOHT) 
predisposition syndrome share the same genetic ger-
mline abnormalities and a link between these two entities 
was established. Some authors have proposed to rename 
SCCOHT as “Rhabdoid tumors of the ovary”. In order to 
accommodate for the rare SMARCB1-negative ovarian rhab-
doid tumors we have chosen to keep the term as it is until 
further defining analyses have been presented.
Within two independent families affected by MRT as 
well as SCCOHT, a SMARCA4 germline PV was demon-
strated [27, 28]. One might speculate that female survivors 
of RTPS2 in infancy could later develop SCCOHT, which 
has been demonstrated in prepubertal females [29]. It is 
noteworthy that no patient with SCCOHT published to date 
developed MRT during infancy. Apart from SCCOHT, ger-
mline truncating PVs of SMARCA4 have also been associ-
ated with undifferentiated uterine sarcomas [30] and a single 
case of BRG1/SMARCA4-deficient lung carcinoma [31].
Specific phenotype of distal congenital 22q11.2 
deletion
In some cases, RTPS1 may be due to a distal deletion of 
22q11.2, encompassing SMARCB1. The phenotype is vari-
able depending on the extent of the deletion, but may consist 
of intra-uterine and post-natal growth retardation, speech 
delay, behavioral problems, and minor dysmorphic fea-
tures [22, 32, 33]. The largest genomic deletions are asso-
ciated with a phenotype overlapping with the velo-cardio-



























Fig. 1  Epidemiological features of SMARCB1 pathogenic vari-
ants (PVs), based on 179 cases reported in the literature. a Propor-
tion of each phenotype observed with the various types of variants; 
WGD whole gene deletion, indel base insertion or deletion leading to 
frameshift, ex.dup/del exon duplication or deletion, PSC premature 
stop codon, SS splice site variant, mis missense variant. b Rhabdoid 
tumor free survival among patients screened for SMARCB1 PV and 
reported in the literature; this illustrates the compilation of reported 
cases with a personal or family history of RT and a germline PV in 
SMARCB1. Penetrance might be biased toward that of high-risk indi-
viduals, but the compilation of reported cases with a personal or fam-
ily history of RT and a germline PV in SMARCB1. Sources [3, 7, 8, 
17, 20–22, 32–35, 45, 48, 57, 60, 73–82]
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be extrapolated for patients with distal 22q11.2 deletion 
syndrome, but deletions encompassing SMARCB1 should 
receive vigilant surveillance from birth to adulthood as large 
deletions may predispose to late occurrence of MRT [22, 
36].
Coffin Siris syndromes and an associated risk 
for neoplasm
Coffin Siris syndrome (CSS) is a rare genetic disorder 
characterized by learning difficulties, coarse facial fea-
tures, hypertrichosis, and hypoplasia of the fifth digits/
nails of the hands and feet. A minority of cases is due to a 
PV in SMARCB1 or SMARCA4. Most PV in SMARCB1 are 
in-frame deletions within exon 9, a genotype exclusively 
reported in CSS and thus far not related to any malignancy. 
Another substantial number of cases of CSS are due to 
missense PV in the last 2 exons of SMARCB1 [37], quite 
similar to those reported in schwannomatosis. Consist-
ently, a patient with CSS affected by schwannomatosis and 
a missense PV in SMARCB1 has been reported [38]. How-
ever, patients with MRT are missing from the literature 
indicating a specific tumor risk associated with this rare 
genotype in CSS. A few additional cases of CSS have been 
linked to SMARCA4 PV. In a series of 15 patients with CSS  
and SMARCA4 PV, Li et al. reported two individuals with 
nonsense variants, associated with a milder phenotype; 
in the two male patients no tumor was reported by ages 
9 and 15 years respectively [39]. By contrast, one patient 
with a mild CSS phenotype related to a truncating variant 
c.2935C > T;p.Arg979* developed a SCCOHT [40], again 
suggesting that detection of truncating SMARCA4 vari-
ants in females justifies surveillance for SCCOHT [40], 
suggesting that detection of this particular genotype in 
females justifies surveillance for SCCOHT. None of the 
13 patients with a missense SMARCA4 PV in the series 
by Li et  al. developed any tumor; similarly, no tumor 
was detected in the series by Sekiguchi et al. reporting 7 
patients (5 males) with all missense variants in SMARCA4 
[37]. Reciprocally, at least two SCCOHT patients without 
other signs of CSS harbor ‘CSS-like’ missense PV in the 
helicase domain of SMARCA4 [41] (Fig. 2a). Altogether, 
the risk in CSS to develop tumors seems to be low, but 
remains difficult to estimate [42, 43]. Specific genotypes 
might need surveillance.
Outcome of patients with RTPS1 and RTPS2
Prognosis of MRT in the frame of RTPS appears to be infe-
rior to sporadic tumors [16, 44], and this seems to be true 
for SMARCB1 as well as for SMARCA4 associated RTPS. 
While rhabdoid tumors associated with RTPS1 exhibit an 
overall survival of 10–20% [7, 44], a total of six out of seven 
patients with ATRT and RTPS2 died within 20 months in the 
series by Hasselblatt et al. [9] (Fig. 2b). The dismal prog-



























Fig. 2  Epidemiological features of SMARCA4 pathogenic variants, 
based on 70 cases (65 published, 5 author’s own unpublished cases). 
a proportion of each phenotype observed with the various types of 
variants; b rhabdoid tumor (orange line: eMRT; blue line: ATRT) 
and SCCOHT (red line) free survival among patients screened for 
SMARCA1 PV and reported in the literature; this graph does not illus-
trate the real penetrance, but the compilation of reported and personal 
cases with a personal or family history of RT and a germline PV in 
SMARCA4. Sources: [9, 27, 41, 83–86]
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Screening for germline PV in SMARCA4 
and SMARCB1
Why should all patients affected by MRT be tested?
Participants of the consensus meeting agreed on the utility 
of genetic counseling and testing in patients with MRT.
The main purpose of genetic testing will be
(1) to answer questions regarding the potential genetic 
cause of the disease,
(2) to reassure parents about the absent (or low) MRT risk 
in siblings, when no PV can be identified in the ger-
mline,
(3) to offer prenatal diagnosis in cases of RTPS in the 
proband, and finally
(4) to offer a cancer surveillance schedule.
Reports on late occurrences of secondary rhabdoid and 
other tumors in patients cured from a first MRT have been 
accumulating [45–47]. This further justifies systematic 
genetic screening for all patients with MRT. It also illus-
trates that SMARCB1-deficient non-MRT neoplasms may 
be part of the RTPS spectrum.
Should we test patients with SMARCB1‑deficient 
non rhabdoid tumors?
SMARCB1-deficient non-MRT neoplasms of childhood 
represent an expanding spectrum of diseases including 
highly aggressive but also low-grade neoplasias [19, 48] 
such as undifferentiated chordomas, epithelioid sarco-
mas, epithelioid MPNST, and other rare entities [49]. One 
case of a SMARCB1 PV with SCCOHT is also on record 
[50]. Employing readily available BAF47 immunostain-
ing, SMARCB1-deficient tumors may be rapidly identi-
fied. At present, there is no evidence in the literature that 
SMARCB1-deficient cancers other than MRT necessitate 
genetic counseling and testing. In particular, no familial 
cases of epithelioid sarcomas or undifferentiated chor-
domas have been reported so far. Nonetheless, the panel 
argues that patients with “SMARCB1-deficient non-RT 
neoplasms” should be offered genetic testing on a research 
basis and, if positive for a PV, cancer surveillance ideally 
in the setting of a tumor predisposition clinic. Regardless 
of the fact that little is known about the penetrance of 
non-rhabdoid SMARCB1-deficient tumors in RTPS, it has 
been generally accepted that any rare cancer in childhood 
justifies discussion and referral to genetic testing. More 
evidence from accumulated data will help to establish the 
clinical and thus individual benefit in the future [51–54].
Should we test unaffected relatives?
Agreement has been reached that clinical surveillance 
should include pre-symptomatic carriers especially when 
a first-degree relative has been diagnosed with active dis-
ease. This initially includes the affected patients’ parents. 
Identification of a PV in an unaffected parent remains an 
exceptional event. Nevertheless, familial recurrence despite 
unremarkable sequencing results in the parents has occasion-
ally been reported, suggesting gonadal mosaicism [3, 7, 8, 
55]. Thus, siblings of children with RTPS should be offered 
genetic screening as well, provided that clinical surveillance 
will be accepted, in case of detection of a PV in the ger-
mline. Given the rather high penetrance, the young median 
age at tumor occurrence and the severity of the disease, it is 
justified to discuss prenatal diagnosis in parents and siblings 
once RTPS has been identified in the proband [55].
Who should be tested for RTPS2?
Regarding SMARCA4, there is an agreement to recom-
mend systematic genetic counseling to all children with 
either BRG1-deficient MRT or SCCOHT. This statement 
is justified due to the serious impact of knowing about a 
SMARCA4 PV for all females in a pedigree. Recommenda-
tions for patients with SCCOHT and families without MRT 
have been developed and are discussed elsewhere [56].
Molecular testing and interpretation 
of the risk according to PV type
Molecular testing: what should not be missed?
SMARCB1 comprises nine exons and produces a 1.749-bp 
transcript variant 1 which encodes the isoform A (RefSeq 
NM_003073.5). Nonsense, frameshift, whole and partial 
gene deletions have been reported in RTPS1. Hence, genetic 
screening should allow for the identification of any of those 
PV types. Classical approaches combine Sanger sequencing 
of the nine coding exons and the intron-to-exon bounda-
ries plus multiplex ligation-dependent probe amplification 
(MLPA) to identify intragenic deletions or duplications. 
Such approaches may be replaced by high-coverage dedi-
cated next-generation sequencing techniques spanning all 
exons of SMARCB1 supplemented by copy number analyses.
Sequencing coding sequences may only miss deep intronic 
PVs in the germline. At least one deep intronic hot-spot has 
previously been reported in intron 1 [57]. In consequence, we 
recommend that intron 1 should be incorporated in future NGS 
screening approaches. In general, identification of the two 
inactivating genetic events in a tumor genome is recommended 
before any conclusion may be drawn on the germline status. 
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Moreover, the augmented depth of sequencing may support 
the discovery of a low frequency of mosaicism, which other-
wise will escape the detection threshold of Sanger sequencing 
(< 10%).
For SMARCA4, multiple transcript variants encoding 
different isoforms have been described. By convention, 
PVs are numbered based on the sequence of the transcript 
encoding the longest isoform, comprising 36 exons (RefSeq 
NM_001128849.1). Given the length of the gene, capture-
based sequencing facilitates genetic screening and will in most 
circumstances now be preferred over Sanger techniques.
The interpretation of PV: what is their impact 
on cancer surveillance?
The interpretation of the variants will follow classical algo-
rithms [58, 59]. However, it should be noticed that RTPS1 is 
almost exclusively associated with highly deleterious variants, 
i.e. those inducing inactivating truncation or copy loss [60].
Thus, the need for surveillance is undisputed in cases of 
premature stop codons, insertions and deletions leading to 
frameshift or whole gene loss. This is not at all clear-cut in 
the case of variants affecting splice sites as most of these 
variation types have been associated with schwannomato-
sis only (Fig. 1a). Nonetheless, compiled data from the lit-
erature estimate the risk of MRT with splice-site PV above 
10%, encouraging similar surveillance for affected patients 
even if the penetrance appears less pronounced (Fig. 1b). 
The impact of the 3′ or 5′ location of such PV and the 
hypothetical level of residual normal protein has not been 
assessed, but may affect the tumor phenotype [61, 62]. On 
the contrary, missense variations have been associated with 
schwannomatosis and surveillance should follow published 
recommendations [63]. Thus far only one case of a mis-
sense PV (c.1142C>G; p.Thr381Arg) has been described 
in a patient suffering from a CRINET, cribriform neuroep-
tithelial tumour [16]. Due to the rarity of this event, the 
incidental finding of a missense PV, which does not cause 
inactivation of the protein in a tumor-free patient will likely 
not lead to an increased risk of malignancy and may not 
prompt the intense surveillance recommended for patients 
with RTPS. However, in case of the unsolicited finding of a 
SMARCB1 missense variant predicted to be pathogenic, we 
strongly recommend the involvement of experts to determine 
the clinical relevance of the variant.
Surveillance strategies for patients 
with RTPS1 and RTPS2
The paucity of reliable clinical data poses a major chal-
lenge in defining genetic screening and clinical surveillance 
recommendations for unaffected PV carriers (i.e. detected 
incidentally or by targeted analyses of families), and for 
patients who have already gone through a tumor disease 
and who survived.
Review of current screening recommendations 
for RTPS1
As knowledge on RTPS has emerged and technology 
advanced (e.g. whole-body MRI, NGS technology) detailed 
surveillance guidelines for RTPS have been provided among 
others by Teplick et al., Foulkes et al. and Nemes and col-
leagues [64–66].
While Teplick et al. and Nemes et al. dichotomized their 
recommendation to children below 1 year and those between 
1–4 (5) years, Foulkes and colleagues focused on all patients 
below 5 years of age. The recommendations likely reflect 
different health care systems as well as different institutional 
preferences. Teplick and Nemes recommend monthly head 
ultrasound in patients below 1 year, Foulkes on the other 
side proposes MRI of the CNS in three-monthly intervals. In 
contrast, while Nemes et al. suggest whole-body MRI every 
3 months in patients at risk between 1 and 5 years of age, 
Foulkes and colleagues leave the issue open.
Very recently an excellent status paper on the current 
evidence, practical clinical approach for genetic testing and 
surveillance as well as research issues in SCCOHT has been 
published. We would like to point the reader to this manu-
script for into-depth information and advice [56].
What screening tools should be used?
Given the unpredictable location of MRT anywhere in the 
body, whole-body MRI (WBMRI) is an option, provided 
that it can be complemented with a CNS MRI for more accu-
rate assessment of the brain and the spine [67]. The use of 
WBMRI, including legs and arms, clearly depends on the 
availability and resources of the respective national health 
care system and institution; where WBMRI is not available, 
clinical examination supplemented by ultrasonography and 
CNS MRI can be discussed as an alternative.
Screening schedule for RTPS1—a proposal 
of the SIOPE Host Genome Working Group
Different rules may apply for MRT survivors, children being 
treated for an MRT, and unaffected carriers. For unaffected 
carriers, surveillance should start as soon as possible, i.e. 
at birth for newborns diagnosed through prenatal diagno-
sis or with 22q11.2 distal deletion syndrome. Considering 
the rapidity of MRT development for infants and other very 
young children, the SIOPE host genome working group sug-
gests choosing surveillance intervals at close time points. 
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The main objective is to diagnose tumors at a stage on which 
a complete resection is still possible (Tables 1 and 2).
Up to 6 months of age we would mandate thorough clini-
cal examination, including subcutaneous tissues at intervals 
of 4–6 weeks in a specialized facility. As MRI may be pos-
sible without general anesthesia in many instances, we sug-
gest to regularly image by WBMRI and MRI of the CNS. 
The panel argued in favour of a 4–6 weeks interval wherever 
possible, not exceeding 2–3 months in any case. As such an 
intense surveillance program will be needed only on rather 
rare occasions but will likely still not be possible in many 
health care systems, we suggest to make an attempt to make 
it part of a research program wherever feasible.
In older children, the need for anesthesia or sedation 
becomes an issue and the refering physician may decide 
against imaging modalities such as WBMRI and CNS MRI 
at close intervals. Alternatively, instead of WBMRI, CNS 
MRI could be coupled with abdominal ultrasonography and 
careful clinical examination of all soft-tissue parts. Keeping 
a close 4–6-week interval for imaging beyond 6 months 
of age appeared unrealistic to the panel, who proposed to 
increase the intervals to 2–3 months, lasting until at least 
36 months of age (Table 2).
The risk of developing a new onset RT dramatically 
decreases after 5 years of age [8]. It remains worthwhile, 
however, to screen individuals with RTPS, for MRT as well 
as for other manifestations (e.g., schwannomas, meningi-
omas, MPNST) [68, 69]. A practical approach includes 
physical examinations every 6 to 12 months with targeted 
imaging for symptomatic areas (e.g., neurologic deficit, 
change in physical features, menstrual disturbances), ide-
ally in the setting of a tumor predisposition clinic [70]. CNS 
MRI and ultrasonography may be discussed.
In unaffected carrier parents, the risk for MRT is com-
pletely unevaluated. Nonetheless, a few case reports exem-
plify the remaining threat throughout life [7, 21, 23, 36]. 
Whether this justifies long-term systematic clinical surveil-
lance could be debated given the presumably rather low risk. 
Table 1  Current general recommendations for clinical surveillance in RTPS1 and RTPS 2
(1) Evaluate all patients with a signal tumor (i.e. Rhabdoid Tumor or SCCOHT) for a germline (GLM) mutation regardless of age
(2) Offer expert genetic counselling to all patients with a PV in the GLM in SMARCB1 or SMARCA4 regardless of age
(3) Offer genetic testing and counselling to all first-degree relatives of a patient with a PV in the GLM in SMARCB1 or SMARCA4 regardless 
of age; this may include prenatal testing
(4) Initiate clinical surveillance of patients and first-degree relatives with a PV in SMARCB1 or SMARCA4 as early as possible (e.g. at birth)
(5) Clinical surveillance should at least consist of ultrasound and clinical examination (i.e. neurological and developmental exam). Intervals for 
whole-body and CNS MRI (and the subsequent need for anesthesia or deep sedation) vary widely. They depend on institutional and/or health 
care system resources but also on physician/proband preference
Table 2  Proposal for 
surveillance program for 
patients/probands with RTPS 
1 (i.e. with a SMARCB1 PV in 
the GLM)
a Depending on resources and need for anesthesia
b Recommendations are subject to continuous adaptations
c Patients with a missense mutation may need distinct surveillance
d This intensive surveillance program may not be possible in many instances and potentially has to be made 
part of research projects; the panel justifies the proposal by the fact, that the risk for tumor occurrence is 
highest within this age group and timeframe
Age Type of exam Intervals (comment)b
All Whole body MRI (WBMRI) At diagnosis for all 
patients with  PVc 
in SMARCB1
0–6 mos MRI CNS incl. spine or CNS ultrasound or  WBMRIa Every 4 weeks, not 
less than every 2–3 
 monthsd
Ultrasound abdomen plus soft tissues (e.g. neck)
Thorough clinical exam incl. neurologic
7–18 mos MRI CNS incl. spine Every 2–3 months
Ultrasound abdomen plus soft tissues (e.g. neck)
Thorough clinical exam incl. neurologic
19 mos–5 years MRI CNS incl. spine Every 3 months
Ultrasound abdomen plus soft tissues (e.g. neck)
Thorough clinical exam incl. neurologic
 > 5 years Whole body MRI Yearly
Physical examination Every 6 months
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However, one can assume that education for early medical 
advice in case of symptoms, and early targeted imaging, is 
a minimalistic option.
Discussion regarding surveillance for MRT 
in patients with RTPS 2
In a meta-analysis of publicly available data sets, Holsten 
and colleagues detected SMARCA4 PVs as the cause of a 
rhabdoid tumor in 8/60 PV carriers, indicating incomplete 
penetrance [16]. Hence, patients with a SMARCA4 germline 
PV seem to develop MRT with a much lower incidence than 
patients with a SMARCB1 germline PV. However, the prog-
nosis of children affected by RTPS2 seems to be as poor 
or even poorer than the one for patients with RTPS1 [9]. 
This suggests offering similar clinical surveillance to these 
patients as the one described for RTPS1 (Tables 1 and 2).
Consistently, germline investigation and if applicable sur-
veillance should be proposed to all first-degree relatives of 
patients affected by SCCOHT who are below 36 months of 
age. International sharing of clinical experience is deeply 
warranted to evaluate whether such a proposal is realistic 
and actually brings any benefit to patients and their families.
As SCCOHT affect females from 5 to 46 years of age, 
clinical surveillance for RTPS2 individuals may not stop 
after 5 years of age, but rather change focus from the RT 
spectrum to include the ovaries. In children and teenagers, 
abdominal-pelvic ultrasonography will be preferred since it 
most often remains sufficiently informative in this age range. 
The issue of prophylactic risk reducing bilateral salpingo-
oophorectomy (RRBSO) and its medical as well as ethical 
ramifications deserve major attention and interdisciplinary 
approach not only towards counselling but also towards 
research [71, 72].
Conclusion: research issues
While the necessity of a clear guidance for clinicians is 
undoubted, it has to be kept in mind that the current guide-
lines rely on limited data and will remain “work-in-progress” 
until sufficient real-world evidence can be put forward.
Unresolved issues that deserve further international 
research endeavors include:
(1) To demonstrate the clinical benefit of the surveillance 
guidelines for unaffected carriers; given the rarity of 
such conditions, international data sharing is war-
ranted.
(2) To follow up on aspects of feasibility, psychological 
burden and cost of such recommendations.
(3) To evaluate the penetrance in children with 22q11.2 
deletions syndromes encompassing SMARCB1; work-
ing with geneticists who follow these patients for non-
tumor symptoms is critical.
(4) To evaluate the incidence of mosaicism in the MRT 
population, and in parents of probands with MRT; to 
evaluate the tumor risk in case of mosaicism.
(5) To evaluate the risk of MRT in offspring of patients 
with SCCOHT and vice versa; to search for putative 
modifiers that may influence the risk for one or another 
tumor type; to support decisions about the risk reducing 
prophylactic salpingo-oophorectomy [56].
(6) To evaluate the tumor spectrum and tumor risk in older 
children, teenagers and adult pre-symptomatic carriers; 
to specify how long surveillance is needed.
(7) To determine the actual need for germline testing in 
children with non rhabdoid SMARCB1-deficient 
tumors.
The SIOPe HGWG and other SIOP collaborative groups 
will now strive to set up an international network allowing to 
address these issues and to further evaluate how to better help 
families affected by such a devastating malignancy.
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